High Cancer Drug Prices: The Harm to Americans and Proposed Solutions
Kantarjian, Hagop; Ho, Vivian
High cancer drug prices significantly contribute to health care costs in the United States, with the average annual price of new cancer drugs increasing from less than $10,000 before 2000 to $145,000 in 2015. Baker Institute fellows Hagop M. Kantarjian and Vivian Ho highlight this issue and propose possible solutions. This policy brief is part of a series of recommendations (http://www.bakerinstitute.org/research/recommendations-president/) from the Baker Institute for the incoming president’s administration.